other primary study · 2017
“After accounting for differences in implementation and settings, the ERSPC and PLCO provide compatible evidence that screening reduces PC mortality.”
Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Ann Intern Med
Who: individual records of men aged 55-69 (ERSPC) and 55-74 (PLCO) at randomization in the two RCTs, analysed jointly with CISNET models
PMID 28869989
pooled analysis · 2026 · read from the abstract
Not counted. Read from the abstract. It could change the badge, so it counts once read in full.
“With 11-23 yr of follow-up, high-certainty evidence demonstrates that PSA-based PCa screening is associated with reduced PCSM among individuals who engage in screening-a finding that contrasts with earlier evidence syntheses.”
Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol
Who: 5 RCTs of PSA-based screening vs no screening or usual care in adults with prostates aged 45-80
PMID 42091407